|Day Low/High||2.91 / 3.02|
|52 Wk Low/High||1.35 / 3.39|
Investors considering a purchase of BioScrip Inc stock, but cautious about paying the going market price of $2.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $2.50 strike, which has a bid at the time of this writing of 30 cents.
Appoints Harriet Booker as Senior Vice President, Chief Operating Officer and Danny R. Claycomb as Senior Vice President, Revenue Cycle Management
The most recent short interest data was recently released for the 10/31/2017 settlement date, and BioScrip Inc is one of the most shorted stocks of the Russell 3000, based on 18.82 "days to cover" versus the median component at 5.18. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 2,458,477 share decrease in total short interest for BioScrip Inc , to 18,783,163, a decrease of 11.57% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Legislation Accelerates Medicare Payment of Home Infusion Therapy Services to 2019
Agreement Will Immediately Improve Capital Structure, Provide Operational Flexibility, and Result in Excess of $50 million in Liquidity
In recent trading, shares of BioScrip Inc have crossed above the average analyst 12-month target price of $2.40, changing hands for $2.42/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Q1 Consolidated Revenue of $217.8 Million, loss from continuing operations net of income taxes of $19.0 million and Adjusted EBITDA of $5.2 Million
Appoints Stephen M. Deitsch as Senior Vice President, Chief Financial Officer and Treasurer
Company Expects Improved Profitability Following Termination of Agreement with UnitedHealthcare
Betting on negative reaction to the Fed has not worked well in the past.
Q4 Consolidated Revenue of $240.1 Million, loss from continuing operations net of income taxes of ($5.2) million and Adjusted EBITDA of $9.5 Million
BioScrip, Inc. (NASDAQ:BIOS), a leading national provider of infusion and home care management solutions, announced today it has joined a newly established coalition, Keep My Infusion Care at Home, which spans...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.